# Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

> **NCT00819052** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 445 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Nevirapine XR
- **DRUG:** Nevirapine XR
- **DRUG:** Nevirapine IR

## Key facts

- **NCT ID:** NCT00819052
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2014-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819052, "Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00819052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*